IP Library Granted Patent US 12697307
Granted Patent B2
US 12697307 · App. 17/924,758 · Granted Aug 4, 2026

Compositions and methods related to megakaryocyte-derived extracellular vesicles

Inventor: Jonathan Thon (Cambridge, MA)
Assignee: STRM.bio Incorporated
A61K9/5068A61K9/127A61K35/19A61K48/0033C12N5/0644C12N13/00C12N2506/03C12N2506/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697307
App. No.
17/924,758
Granted
Aug 4, 2026
Kind
B2
Abstract

Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.

Claims (20)

1 . A composition comprising:

a plurality of megakaryocyte-generated extracellular vesicles (MkEVs) comprising a lipid bilayer membrane surrounding a lumen, wherein:

a. the MkEV lumen comprises one or more nucleic acid molecules from the megakaryocytes selected from mRNA, tRNA, rRNA, siRNA, microRNA, regulating RNA, and non-coding and coding RNA; and,

b. the lipid bilayer membrane comprises one or more proteins associated with or embedded within, wherein the one or more proteins are selected from CD21 and GPVI; and,

C. the MkEVs are isolated from megakaryocytes derived from a human pluripotent stem cell (HPSC).

2 . The composition of claim 1 , wherein the lipid bilayer membrane further comprises one or more of CD9, CD63, CD47, CD43, CD54, and CD18.

3 . The composition of claim 1 , wherein the lipid bilayer membrane further comprises one or more of CD41, CD61, CD11b, LAMP-1 (CD107a), CD51, CD31, CD147, phosphatidylserine, CLEC-2, CD62, CD42b, and CD32a.

4 . The composition of claim 1 , wherein the MkEVs are of a diameter in the range between 100 nm to 300 nm.

5 . The composition of claim 1 , wherein the MkEVs are essentially free of:

a. megakaryocytes, and/or

b. platelets

C. organelles, and/or

d. mitochondria or nuclei.

6 . The composition of claim 1 , wherein the MkEVs are suitable for homing to a hematopoietic stem cell, a bone marrow, a lymphatic cell, or a regulatory T cell in vivo and/or in vitro.

7 . The composition of claim 1 , wherein the MkEVs are suitable for loading with cargo into the lumen and/or loading with cargo associated with the surface of the MkEVs.

8 . The composition of claim 7 , wherein the cargo is selected from one or more of a RNA, DNA, protein, carbohydrate, lipid, biomolecule, and small molecule.

9 . The composition of claim 8 , wherein the cargo is one or more therapeutic agents.

10 . The composition of claim 9 , wherein the therapeutic agent is selected from one or more of an antibody or an antibody fragment, recombinant protein, fusion protein, gene-editing protein, cytokine, antigen, and peptide.

11 . The composition of claim 9 , wherein the therapeutic agent is a nucleic acid therapeutic agent selected from one or more non-autologous and/or recombinant nucleic acid constructs selected from mRNA, tRNA, rRNA, siRNA, microRNA, regulating RNA, non-coding and coding RNA, linear DNA, DNA fragments, and DNA plasmids.

12 . The composition of claim 11 , wherein the nucleic acid therapeutic agent encodes a functional protein or a gene-editing protein.